Article Text

other Versions

Download PDFPDF
Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: a case–control study
  1. Marcus Ang1,2,
  2. Alireza Hedayatfar1,
  3. Wanling Wong2,3,
  4. Soon-Phaik Chee1,3
  1. 1Singapore National Eye Centre, Singapore, Republic of Singapore
  2. 2Singapore Eye Research Institute, Singapore, Republic of Singapore
  3. 3Department of Ophthalmology, Yong Yoo Lin School of Medicine, National University of Singapore, Singapore, Republic of Singapore
  1. Correspondence to Associate Professor Soon-Phaik Chee, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751, Republic of Singapore; chee.soon.phaik{at}


Aim To study the effect of the duration of anti-tubercular treatment (ATT) on the recurrence of uveitis associated with latent tuberculosis (TB).

Methods Retrospective review of all consecutive uveitis patients seen at a single, tertiary institution over 9 years with uveitis consistent with TB, positive tuberculin skin test with other causes ruled out, and a minimum of 6 months follow-up after completion of treatment. Clinical characteristics, treatment type, treatment duration and clinical response were recorded. Our main outcome measure was the effect of ATT duration on the recurrence of inflammation.

Results Of the 182 eligible patients, 46 received ATT of ≥6 month's duration; 18 patients defaulted and received <6 months treatment. The patients' mean age was 45.3±13.2 years and most were female (n=118, 57.6%) and of Chinese race (n=104, 50.7%). Patients who completed >9 months ATT were less likely to develop recurrence compared with those not treated with ATT (OR 0.09; 95% CI 0.01 to 0.76; p=0.027), while adjusting for potential confounders such as patient demographics, anatomical location of uveitis and corticosteroid therapy.

Conclusion Patients with uveitis and latent TB treated with ATT of >9 months duration had an 11-fold reduction in the likelihood of recurrence.

  • Choroid
  • infection
  • inflammation
  • immunology
  • iris
  • ciliary body

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None to declare.

  • Patient consent Obtained.

  • Ethics approval Singhealth Institutional Review Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles